Cargando…
P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: OBJECTIVES: This study aimed to investigate the species distribution and susceptibility profiles of Aspergillus species isolated from patients admitted to the intensive care unit with severe COVID-19 in Isfahan, Iran, between April 2021 and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509778/ http://dx.doi.org/10.1093/mmy/myac072.P398 |
_version_ | 1784797303085727744 |
---|---|
author | Fakhim, Hamed vaezi, Afsane nasri, Elahe Sadeghi, Somayeh Shelerangkon, Mahsa Rizi, Mahnaz Hosseini Ghafel, Safiyeh Badali, Hamid Mirhendi, Hossein |
author_facet | Fakhim, Hamed vaezi, Afsane nasri, Elahe Sadeghi, Somayeh Shelerangkon, Mahsa Rizi, Mahnaz Hosseini Ghafel, Safiyeh Badali, Hamid Mirhendi, Hossein |
author_sort | Fakhim, Hamed |
collection | PubMed |
description | POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: OBJECTIVES: This study aimed to investigate the species distribution and susceptibility profiles of Aspergillus species isolated from patients admitted to the intensive care unit with severe COVID-19 in Isfahan, Iran, between April 2021 and March 2022. METHODS: This retrospective study included intubated patients with COVID-19 in three referral COVID-19 hospitals. Tracheal aspirate (TA) samples were taken from 267 patients to investigate pulmonary co-infections. COVID-19-associated aspergillosis (CAPA) was defined according to the 2020 European Confederation of Medical Mycology/International Society of Human and Animal Mycosis consensus criteria. Aspergillus species obtained from samples were characterized based on conventional and molecular assays. In vitro antifungal susceptibility testing was performed on the obtained isolates according to the guidelines from the Clinical and Laboratory Standards Institute. RESULTS: The mean age of the patients was 61.73 ± 12.69 years. The mean length of hospitalization and admission in ICU were 18.77 ± 12.94 and 13.51 ± 9.83 days, respectively. A total of 61 (22.9%) patients presented with a single cavity lesion. Pulmonary artery pseudoaneurysm was seen in seven patients and post-COVID-19 changes were seen in all patients. Based on the conventional and molecular techniques, 72 isolates of Aspergillus species (26.9%), including A. flavus (10.1%%), A. fumigatus (8.6%%), A. niger (3.3%), A. tubingensis (2.9%), A. terreus (1.1%), A. luchuensis (0.37%) A. quadrillineatus, and (0.37%), were obtained from 267 patients. MIC results showed that all Aspergillus species were susceptible to all tested antifungal drugs. CONCLUSION: Access to priority clinical groups, improving the care of patients with simultaneous pulmonary aspergillosis with COVID-19, and identifying Aspergillus species are essential steps in the care cascade to manage those affected by them. |
format | Online Article Text |
id | pubmed-9509778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95097782022-09-26 P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles Fakhim, Hamed vaezi, Afsane nasri, Elahe Sadeghi, Somayeh Shelerangkon, Mahsa Rizi, Mahnaz Hosseini Ghafel, Safiyeh Badali, Hamid Mirhendi, Hossein Med Mycol Oral Presentations POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM: OBJECTIVES: This study aimed to investigate the species distribution and susceptibility profiles of Aspergillus species isolated from patients admitted to the intensive care unit with severe COVID-19 in Isfahan, Iran, between April 2021 and March 2022. METHODS: This retrospective study included intubated patients with COVID-19 in three referral COVID-19 hospitals. Tracheal aspirate (TA) samples were taken from 267 patients to investigate pulmonary co-infections. COVID-19-associated aspergillosis (CAPA) was defined according to the 2020 European Confederation of Medical Mycology/International Society of Human and Animal Mycosis consensus criteria. Aspergillus species obtained from samples were characterized based on conventional and molecular assays. In vitro antifungal susceptibility testing was performed on the obtained isolates according to the guidelines from the Clinical and Laboratory Standards Institute. RESULTS: The mean age of the patients was 61.73 ± 12.69 years. The mean length of hospitalization and admission in ICU were 18.77 ± 12.94 and 13.51 ± 9.83 days, respectively. A total of 61 (22.9%) patients presented with a single cavity lesion. Pulmonary artery pseudoaneurysm was seen in seven patients and post-COVID-19 changes were seen in all patients. Based on the conventional and molecular techniques, 72 isolates of Aspergillus species (26.9%), including A. flavus (10.1%%), A. fumigatus (8.6%%), A. niger (3.3%), A. tubingensis (2.9%), A. terreus (1.1%), A. luchuensis (0.37%) A. quadrillineatus, and (0.37%), were obtained from 267 patients. MIC results showed that all Aspergillus species were susceptible to all tested antifungal drugs. CONCLUSION: Access to priority clinical groups, improving the care of patients with simultaneous pulmonary aspergillosis with COVID-19, and identifying Aspergillus species are essential steps in the care cascade to manage those affected by them. Oxford University Press 2022-09-20 /pmc/articles/PMC9509778/ http://dx.doi.org/10.1093/mmy/myac072.P398 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Oral Presentations Fakhim, Hamed vaezi, Afsane nasri, Elahe Sadeghi, Somayeh Shelerangkon, Mahsa Rizi, Mahnaz Hosseini Ghafel, Safiyeh Badali, Hamid Mirhendi, Hossein P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles |
title | P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles |
title_full | P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles |
title_fullStr | P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles |
title_full_unstemmed | P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles |
title_short | P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles |
title_sort | p398 covid-19-associated pulmonary aspergillosis: species distribution and susceptibility profiles |
topic | Oral Presentations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509778/ http://dx.doi.org/10.1093/mmy/myac072.P398 |
work_keys_str_mv | AT fakhimhamed p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT vaeziafsane p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT nasrielahe p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT sadeghisomayeh p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT shelerangkonmahsa p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT rizimahnazhosseini p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT ghafelsafiyeh p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT badalihamid p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles AT mirhendihossein p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles |